Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Effect of initial treatment on health‐related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry
Abonour, Rafat , Rifkin, Robert M. , Gasparetto, Cristina , Toomey, Kathleen, Durie, Brian G.M. , Terebelo, Howard R. , Narang, Mohit , Ailawadhi, Sikander , Omel, James, Srinivasan, Shankar , Kitali, Amani, Agarwal, Amit , Investigators, the CONNECT MM Registry, Terebelo, Howard R , Ailawadhi, Sikander , Hardin, James W. , Jagannath, Sundar , Lee, Hans C. , Wagner, Lynne I. , Investigators, the CONNECT MM Registry

Mayo Clinic

British Journal of Haematology | October 29, 2020 | Volume: 193 | Issue: 1 | Pages: 93-100

10.1111/bjh.17131 | PMID 33118614 Get It

SummaryAlthough new multiple myeloma (MM) therapies are effective in alleviating some disease‐associated symptoms (e.g. bone pain, fatigue, functional decline), they can result in additional toxicities, further impacting health‐related quality of life (HRQoL). Here, we compared HRQoL and safety of lenalidomide‐bortezomib‐dexamethasone [RVd (n = 445)], bortezomib‐melphalan‐prednisone [VMP (n = 77)] and Vd or VMP (n = 588) in patients with newly diagnosed MM (NDMM) from the Connect® MM Registry, a large, USA, multicentre, prospective observational cohort study. Functional Assessment of Cancer Therapy‐Multiple Myeloma subscale, EuroQol‐5D overall score and Bone Pain Inventory HRQoL scores were significantly improved with RVd versus Vd/VMP. Serious adverse event rates were similar in all groups. Treatment with RVd maintained HRQoL in this real‐world, largely community‐based population of patients with NDMM.
Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis
Bona, Kira , Brazauskas, Ruta , He, Naya, Lehmann, Leslie , Abdel‐Azim, Hisham , Ahmed, Ibrahim , Al‐Homsi, A. Samer, Aljurf, Mahmoud , Arnold, Staci D. , Badawy, Sherif M. , Beattie, Sara , Dalal, Jignesh , Dandoy, Christopher E. , Frangoul, Haydar , Freytes, César O. , Ganguly, Siddhartha , Hahn, Theresa , Kamble, Rammurti T., LeMaistre, Charles F. , Law, Jason , Majhail, Navneet S. , Preussler, Jaime M. , Schears, Raquel M. , Seo, Sachiko , Sharma, Akshay , Steinberg, Amir , Szwajcer, David , Wirk, Baldeep , Khera, Nandita , Wood, William A. , Hashmi, Shahrukh K. , Duncan, Christine , Saber, Wael , Hashmi, Shahrukh, Majhail, Navneet S , Sharma, Akshay , Badawy, Sherif M , Arnold, Staci D , Dandoy, Christopher E , Wood, William A , Battiwalla, Minoo , Bhatt, Neel S. , Díaz, Miguel Ángel , George, Biju , Gómez‐Almaguer, David , Knight, Jennifer M. , Lazarus, Hillard M. , Olsson, Richard F. , Savani, Bipin N. , Srivastava, Alok , Yoshimi, Ayami

Mayo Clinic

Blood | October 26, 2020 | Volume: 137 | Issue: 4 | Pages: 556-568

10.1182/blood.2020006252 | PMID 33104215 Get It

Abstract Social determinants of health, including poverty, contribute significantly to health outcomes in the United States; however, their impact on pediatric hematopoietic cell transplantation (HCT) outcomes is poorly understood. We aimed to identify the association between neighborhood poverty and HCT outcomes for pediatric allogeneic HCT recipients in the Center for International Blood and Marrow Transplant Research database. We assembled 2 pediatric cohorts undergoing first allogeneic HCT from 2006 to 2015 at age ≤18 years, including 2053 children with malignant disease and 1696 children with nonmalignant disease. Neighborhood poverty exposure was defined a priori per the US Census definition as living in a high-poverty ZIP code (≥20% of persons below 100% federal poverty level) and used as the primary predictor in all analyses. Our primary outcome was overall survival (OS), defined as the time from HCT until death resulting from any cause. Secondary outcomes included relapse and transplantation-related mortality (TRM) in malignant disease, acute and chronic graft-versus-host disease, and infection in the first 100 days post-HCT. Among children undergoing transplantation for nonmalignant disease, neighborhood poverty was not associated with any HCT outcome. Among children undergoing transplantation for malignant disease, neighborhood poverty conferred an increased risk of TRM but was not associated with inferior OS or any other transplantation outcome. Among children with malignant disease, a key secondary finding was that children with Medicaid insurance experienced inferior OS and increased TRM compared with those with private insurance. These data suggest opportunities for future investigation of the effects of household-level poverty exposure on HCT outcomes in pediatric malignant disease to inform care delivery interventions.
S3296 Healthcare Provider Satisfaction With Telemedicine During the COVID-19 Pandemic
Bering, Jamie , Ramirez, Francisco C. , Umar, Sarah B.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S1719-S1719

10.14309/01.ajg.0000715232.18788.78 Get It

S0470 The Impact of Plecanatide on Abdominal Pain in Patients With Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation: Analysis From Four Phase 3 Studies
Bharucha, Adil E. , Rosenberg, Jonathan , Patel, Reema, Lorenzen, Sarah, Sayuk, Gregory S.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S236-S236

10.14309/01.ajg.0000703928.35944.4e Get It

S0383 Prevalence of Barrett’s Esophagus in Female Scleroderma Patients
Snyder, Diana L. , Griffing, W. Leroy , Umar, Sarah B. , Ramirez, Francisco C. , Crowell, Michael D. , Kahn, Allon

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S189-S190

10.14309/01.ajg.0000703580.83851.48 Get It

Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States
Hong, Sanghee , Brazauskas, Ruta , Hebert, Kyle, Ganguly, Siddhartha , Abdel‐Azim, Hisham , Beattie, Sara , Ciurea, Stefan O. , Szwajcer, David , Badawy, Sherif M. , Gratwohl, Aloïs , LeMaistre, Charles F. , Aljurf, Mahmoud , Farhadfar, Nosha , Seo, Sachiko , Beitinjaneh, Amer , Sharma, Akshay , Law, Jason , Ulrickson, Matthew L. , Schoemans, Hélène , Černý, Jan , Rizzieri, David A. , Kamble, Rammurti T., Shaw, Bronwen E. , Khera, Nandita , Wood, William A. , Hashmi, Shahrukh K. , Hahn, Theresa , Lee, Stephanie J. , Rizzo, J. Douglas , Majhail, Navneet S. , Saber, Wael , Ciurea, Stefan O , Farhadfar, Nosha , Savani, Bipin N , Shaw, Bronwen E , Khera, Nandita , Hashmi, Shahrukh K , Majhail, Navneet S , Sharma, Akshay , Badawy, Sherif M , Lee, Stephanie J , Wood, William A , Díaz, Miguel Ángel , Olsson, Richard F. , Bhatt, Neel S. , Yared, Jean A. , Yoshimi, Ayami , Gergis, Usama , Lazarus, Hillard M. , Hashem, Hasan , Savani, Bipin N.

Mayo Clinic

Cancer | October 21, 2020 | Volume: 127 | Issue: 4 | Pages: 609-618

10.1002/cncr.33232 | PMID 33085090 Get It

BackgroundThe association of community factors and outcomes after hematopoietic cell transplantation (HCT) has not been comprehensively described. Using the County Health Rankings and Roadmaps (CHRR) and the Center for International Blood and Marrow Transplant Research (CIBMTR), this study evaluated the impact of community health status on allogeneic HCT outcomes.MethodsThis study included 18,544 adult allogeneic HCT recipients reported to the CIBMTR by 170 US centers in 2014‐2016. Sociodemographic, environmental, and community indicators were derived from the CHRR, an aggregate community risk score was created, and scores were assigned to each patient (patient community risk score [PCS]) and transplant center (center community risk score [CCS]). Higher scores indicated less healthy communities. The impact of PCS and CCS on patient outcomes after allogeneic HCT was studied.ResultsThe median age was 55 years (range, 18‐83 years). The median PCS was –0.21 (range, –1.37 to 2.10; standard deviation [SD], 0.42), and the median CCS was –0.13 (range, –1.04 to 0.96; SD, 0.40). In multivariable analyses, a higher PCS was associated with inferior survival (hazard ratio [HR] per 1 SD increase, 1.04; 99% CI, 1.00‐1.08; P = .0089). Among hematologic malignancies, a tendency toward inferior survival was observed with a higher PCS (HR, 1.04; 99% CI, 1.00‐1.08; P = .0102); a higher PCS was associated with higher nonrelapse mortality (NRM; HR, 1.08; 99% CI, 1.02‐1.15; P = .0004). CCS was not significantly associated with survival, relapse, or NRM.ConclusionsPatients residing in counties with a worse community health status have inferior survival as a result of an increased risk of NRM after allogeneic HCT. There was no association between the community health status of the transplant center location and allogeneic HCT outcomes.
Galactose treatment of a PGM1 patient presenting with restrictive cardiomyopathy
Donoghue, Sarah , White, Susan M. , Kowalski, Remi , Yaplito‐Lee, Joy , Donoghue, Sarah E , Tan, Tiong Yang , Morava, Éva

Mayo Clinic

JIMD Reports | October 20, 2020 | Volume: 57 | Issue: 1 | Pages: 29-37

10.1002/jmd2.12177 | PMID 33473337 Get It

AbstractWe report a patient diagnosed with PGM1‐CDG at 11 years of age after two biallelic likely pathogenic variants in PGM1 were found on research genomic sequencing. To our knowledge, he is the first patient with PGM1‐CDG to be reported with a restrictive cardiomyopathy. Other clinical manifestations included cleft palate, asymptomatic elevated transaminases, intellectual disability and myopathy resulting in exercise intolerance. He was trialed on oral galactose therapy in increasing doses for 18 weeks to assess if there was any biochemical and clinical benefit. His galactose was continued for a further 9 months beyond the initial galactose treatment period due to improvements in exercise tolerance and myopathy. Treatment with galactose demonstrated an improvement in liver function and myopathy with improved exercise tolerance. Treatment with galactose for 15 months did not change heart function and exercise stress test results were stable.
A Systematic Review of Peripheral Neuropathies in Breast Cancer–Related Lymphedema
Forte, Antonio J. , Huayllani, María T. , Manrique, Oscar J. , Lu, Xiaona , McLaughlin, Sarah A. , Kung, Theodore A. , Boczar, Daniel , Forte, Antonio Jorge

Mayo Clinic

HAND | October 19, 2020 | Volume: 17 | Issue: 4 | Pages: 668-675

10.1177/1558944720963944 | PMID 33073616 Get It

Controversy exists regarding the influence of breast cancer–related lymphedema (BCRL) in the development of peripheral neuropathies. Our aim was to evaluate the association of secondary lymphedema with peripheral neuropathies in patients with breast cancer. We performed a systematic review by querying PubMed, EMBASE, Ovid Medline and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, and Cochrane Central Register of Controlled Trials databases. The keywords “lymphedema” AND (“neuropathy” OR “carpal tunnel syndrome” OR “cubital tunnel syndrome” OR “neuropathic pain”) and synonyms in titles and abstracts were used to perform the search. Seventeen articles met the inclusion criteria. Discrepancies were found in studies that analyzed whether a cause-effect association exists between carpal tunnel syndrome (CTS) and secondary lymphedema. No evidence indicated that lymphedema predisposes to developing peripheral neuropathies such as CTS or brachial plexopathy. No studies found an association between patients with breast cancer at risk of or with lymphedema and the development or worsening of CTS. Carpal tunnel release can be safely performed in patients with BCRL. Neuropathic pain worsens with lymphedema, and treatment seems to improve the pain. Our study did not find enough evidence to conclude that BCRL is associated with the development of peripheral neuropathies. Carpal tunnel release is a safe procedure that can be performed in patients with BCRL and does not influence the development or worsening of lymphedema. Neuropathic pain seems to worsen after development of lymphedema, and treatment has been found to improve neuropathic pain.
Implantation of leadless pacemakers via inferior vena cava filters is feasible and safe: Insights from a multicenter experience
Houmsse, Mahmoud , Karki, Roshan , Gabriels, James , Reinig, Michael, Patel, Dilesh, Hussain, Sarah, Gandhi, Gaurang , Lloyd, Michael S. , Patel, Apoor , Afzal, Muhammad R. , Cha, Yong‐Mei , Cha, Yong-Mei , Makary, Mina S. , Okabe, Toshimasa , Tamirisa, Kamala P. , Joza, Jacqueline E. , Epstein, Laurence M.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | October 15, 2020 | Volume: 31 | Issue: 12 | Pages: 3277-3285

10.1111/jce.14776 | PMID 33058275 Get It

AbstractBackgroundThe leadless Micra transcatheter‐pacing system (Micra‐TPS) is implanted via a femoral approach using a 27‐French introducer sheath. The Micra Transcutaneous Pacing Study excluded patients with inferior vena cava (IVC) filters.ObjectiveTo examine the feasibility and safety of Micra‐TPS implantation through an IVC filter.MethodsThis multicenter retrospective study included patients with an IVC filter who underwent a Micra‐TPS implantation. Data for clinical and IVC filter characteristics, preprocedure imaging, and procedural interventions were collected. The primary outcome was a successful leadless pacemaker (LP) implantation via a femoral approach in the presence of an IVC filter. Periprocedural and delayed clinical complications were also evaluated.ResultsOf the 1528 Micra‐TPS implants attempted, 23 patients (1.5%) had IVC filters. The majority (69.6%) of IVC filters were permanent. Six (26.1%) patients underwent preprocedural imaging to assess for filter patency. One patient's filter was retrieved before LP implantation. The primary outcome was achieved in 21 of 22 patients (95.5%) with an existing IVC filter. An occluded IVC precluded LP implantation in one patient. Difficulty advancing the stiff guidewire or the 27‐Fr sheath was encountered in five patients. These cases required repositioning of the wire (n = 2), gradual sheath upsizing (n = 2), or balloon dilation of the filter (n = 1). Postprocedure fluoroscopy revealed intact filters in all cases. During a median 6‐month follow‐up, there were no clinical complications related to the filter or the Micra‐TPS.ConclusionThis multicenter experience demonstrates the feasibility and safety of Micra‐TPS implantation via an IVC filter without acute procedural or delayed clinical complications.
Prenatal characterization of a novel inverted SMAD2 duplication by mate-pair sequencing in a fetus with dextrocardia
Mendoza, Cinthya Zepeda, Essendrup, Anna, Smoley, Stephanie A., Johnson, Sarah H. , Hoppman, Nicole L., Vasmatzis, George , Jackson, Daniel L. , Kearney, Hutton M. , Zepeda‐Mendoza, Cinthya , Baughn, Linda B.

Mayo Clinic

No container title available | October 1, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.160157600.00947118 Get It

A fetus harboring a duplication of SMAD2 exons 1-6 presented with dextrocardia and pulmonary hypoplasia. Mate-pair sequencing revealed the duplication to be in inverted tandem orientation to the wild-type SMAD2 allele, disrupting its sequence and decreasing expression. These observations suggest SMAD2 to be responsible for the fetal dextrocardia.